安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Home - SOFIE
Our vision is to improve patient outcomes by developing and delivering molecular diagnostics and therapeutics (theranostics)
- Find a Radiopharmacy - SOFIE
SOFIE is dedicated to providing reliable, high quality radiopharmaceuticals and cutting-edge technologies
- Who We Are - SOFIE
We are dedicated to improving patient outcomes by developing, supplying and delivering molecular diagnostics and therapeutics (theranostics)
- SOFIE Biosciences Announces First Patient Dosed in [18F]FAPI-74 Phase 3 . . .
SOFIE Biosciences today announced that the first patient has been dosed in its Phase 3 clinical trial evaluating [18F]FAPI-74, a fluorine-18 labeled radiopharmaceutical targeting Fibroblast Activation Protein (FAP), as a novel diagnostic for patients with Pancreatic Ductal Adenocarcinoma
- SOFIE drives U. S. manufacture of [18F]FAPI-74 - SOFIE
Seven SOFIE radiopharmacies now produce the FAP-targeting radiopharmaceutical, as SOFIE launches Phase 3 clinical trials and support of Pharma and Academic groups Map shows planned [18F]FAPI-74 U S Coverage for 2026 Kansas City, MO, and Houston, TX, are the latest SOFIE radiopharmacies cleared to manufacture [18F]FAPI-74, bringing the total number of sites to seven The other locations
- Network - SOFIE
SOFIE has built a high-capacity PET radiopharmaceutical network capable of delivering large volumes of products to as many patients as possible Our product lines include FDG, Pylarify, Neuraceq, and other clinical trial products
- SOFIE activates FAPI-GO, first [18F]FAPI-74 Phase 3 trial - SOFIE
Another defining moment for SOFIE Biosciences! Last Friday, November 14, 2025, FAPI-GO, SOFIE’s FAPI-74 Phase 3 study in gastroesophageal cancers, officially went live! The first site, a collaboration with Helios Clinical Research and RadNet, has been activated and is ready to enroll patients SOFIE plans to activate 18 total sites across the country over the next
- SOFIE’s Phase 2 FAPI Study Outcomes Showcased at ASCO GI 2026 - SOFIE
Results from SOFIE’s Phase 2 diagnostic study on [18 F]FAPI-74 PET were presented to the oncological community at the esteemed ASCO Gastrointestinal (GI) Cancers Symposium held in San Francisco January 8-10, 2026 The multi-center trial showed that [18 F]FAPI-74 PET detects FAP expression and presence of disease in cancers of the gastrointestinal tract, with high positive predictive values
|
|
|